{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:27:53Z","timestamp":1790659673652,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40265-021-01597-9","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T06:14:06Z","timestamp":1632896046000},"page":"1763-1774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-773X","authenticated-orcid":false,"given":"Christian","family":"Domingo Ribas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Carrillo D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Blanco Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mart\u00ednez Morag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Banas Conejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Guadalupe","family":"S\u00e1nchez Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the REDES Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Cabrerizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebymar","family":"Arismendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Bobolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Gonz\u00e1lez-Barcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purificaci\u00f3n","family":"P\u00e9rez-L\u00f3pez-Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinto","family":"Ramos-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00edn-Puentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Soto-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"P\u00e9rez-Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Lluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Garc\u00eda-Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Gutierrez-Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoia","family":"Salinas-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleof\u00e9","family":"Fern\u00e1ndez-Aracil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puente-Maestu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walther Iv\u00e1n","family":"Gir\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"G\u00f3mez-Sacrist\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"D\u00edaz-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ross-Monserrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Prina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eusebi","family":"Chiner-Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Va\u00f1es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"D\u00edaz-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Garc\u00eda-Moguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Fern\u00e1ndez-Marrube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Hermida-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00eds","family":"Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Marina-Malanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"G\u00f3mez-Larrauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Garc\u00eda-Dumpi\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Castillo-Sainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Cabanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Quirce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Dominguez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Laorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antol\u00edn","family":"L\u00f3pez-Vi\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tris\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Caruana-Careaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"G\u00f3mez-Bastero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Mar\u00edn-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"issue":"suppl 64","key":"1597_CR1","first-page":"4639","volume":"56","author":"CD Ribas","year":"2020","unstructured":"Domingo Ribas C, Sogo Sagardia A, Prina E, Sicras Mainar A, Sicras Navarro A, Engroba Teijeiro C. Prevalence, characterization and costs of severe asthma in Spain (BRAVO 1). Eur Respir J. 2020;56(suppl 64):4639.","journal-title":"Eur Respir J"},{"issue":"2","key":"1597_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"1597_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0300-2896(15)32812-X","volume":"51","author":"V Plaza Moral","year":"2015","unstructured":"Plaza Moral V. GEMA(4.0). Guidelines for asthma management. Arch Bronconeumol. 2015;51(Suppl 1):2\u201354.","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"1597_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","volume":"135","author":"PW Hekking","year":"2015","unstructured":"Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896\u2013902.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1597_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","volume":"108","author":"F Schleich","year":"2014","unstructured":"Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, et al. Heterogeneity of phenotypes in severe asthmatics: The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108(12):1723.","journal-title":"Respir Med"},{"key":"1597_CR6","doi-asserted-by":"crossref","unstructured":"The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for understanding mechanisms of severe asthma. Eur Respir J. 2003;22(3):470-7.","DOI":"10.1183\/09031936.03.00261903"},{"issue":"2","key":"1597_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","volume":"119","author":"WC Moore","year":"2007","unstructured":"Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405\u201313.","journal-title":"J Allergy Clin Immunol"},{"key":"1597_CR8","volume-title":"Global strategy for asthma management and prevention","author":"Asthma GIf","year":"2020","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. www.ginasthma.org"},{"issue":"13","key":"1597_CR9","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HGLM Ortega","year":"2014","unstructured":"Ortega HGLM, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207.","journal-title":"N Engl J Med"},{"issue":"13","key":"1597_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189\u201397.","journal-title":"N Engl J Med"},{"issue":"5","key":"1597_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GBE Chupp","year":"2017","unstructured":"Chupp GBE, Albers F, Bratton D, Wang-Jairaj J, Nelsen L, Trevor J, Magnan A, Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390\u2013400.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"1597_CR12","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/all.13850","volume":"74","author":"KRAF Chapman","year":"2019","unstructured":"Chapman KRAF, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716\u201326. https:\/\/doi.org\/10.1111\/all.13850.","journal-title":"Allergy"},{"key":"1597_CR13","doi-asserted-by":"publisher","unstructured":"Enr\u00edquez-Rodr\u00edguez AI, Hermida Valverde T, Romero \u00c1lvarez P, L\u00f3pez-Gonz\u00e1lez FJ, Gull\u00f3n Blanco JA, Exp\u00f3sito Villegas AR, et al. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study. J Asthma. 2021:1\u20137. https:\/\/doi.org\/10.1080\/02770903.2021.1897835","DOI":"10.1080\/02770903.2021.1897835"},{"issue":"4","key":"1597_CR14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00151-2020","volume":"56","author":"T Harrison","year":"2020","unstructured":"Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4): 2000151.","journal-title":"Eur Respir J"},{"key":"1597_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106491","volume":"185","author":"C Crimi","year":"2021","unstructured":"Crimi C, Campisi R, Nolasco S, Cacopardo G, Intravaia R, Porto M, et al. Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study. Res Med. 2021;185: 106491.","journal-title":"Res Med"},{"issue":"9","key":"1597_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100462","volume":"13","author":"C Crimi","year":"2020","unstructured":"Crimi C, Campisi R, Nolasco S, Cacopardo G, Intravaia R, Nolasco S, et al. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Organ J. 2020;13(9): 100462.","journal-title":"World Allergy Organ J"},{"issue":"2","key":"1597_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","volume":"158","author":"JE Kavanagh","year":"2020","unstructured":"Kavanagh JE, d\u2019Ancona G, Elstad M, Green L, Fernandes M, Thomson L, et al. Real-world effectiveness and the characteristics of a \u201cSuper-Responder\u201d to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491\u2013500.","journal-title":"Chest"},{"key":"1597_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2147\/JAA.S319572","volume":"14","author":"MZ Kayser","year":"2021","unstructured":"Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, et al. Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months. J Asthma Allergy. 2021;14:863\u201371.","journal-title":"J Asthma Allergy."},{"issue":"6","key":"1597_CR19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01444-2018","volume":"52","author":"T Brown","year":"2018","unstructured":"Brown T, Jones T, Gove K, Barber C, Elliott S, Chauhan A, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J. 2018;52(6): 1801444.","journal-title":"Eur Respir J"},{"issue":"1","key":"1597_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","volume":"113","author":"RA Nathan","year":"2004","unstructured":"Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59\u201365.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1597_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jaci.2006.01.011","volume":"117","author":"M Schatz","year":"2006","unstructured":"Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549\u201356.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1597_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","volume":"124","author":"M Schatz","year":"2009","unstructured":"Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P, et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009;124(4):719-23.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"4 Pt 1","key":"1597_CR23","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1164\/ajrccm.162.4.9912033","volume":"162","author":"B Leynaert","year":"2000","unstructured":"Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1391\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1597_CR24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02345-2019","volume":"55","author":"C Taill\u00e9","year":"2020","unstructured":"Taill\u00e9 C, Chanez P, Devouassoux G, Didier A, Pison C, Garcia G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020;55(6): 1902345.","journal-title":"Eur Respir J"},{"key":"1597_CR25","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212584","volume":"8","author":"O Montero-P\u00e9rez","year":"2019","unstructured":"Montero-P\u00e9rez O, Contreras-Rey MB, S\u00e1nchez-G\u00f3mez E. Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice. Drugs Context. 2019;8: 212584.","journal-title":"Drugs Context."},{"issue":"6","key":"1597_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/cea.13601","volume":"50","author":"F Schleich","year":"2020","unstructured":"Schleich F, Graff S, Nekoee H, Moermans C, Henket M, Sanchez C, et al. Real-word experience with mepolizumab: does it deliver what it has promised? Clin Exp Allergy. 2020;50(6):687\u201395.","journal-title":"Clin Exp Allergy"},{"key":"1597_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101836","volume":"58","author":"D Bagnasco","year":"2019","unstructured":"Bagnasco D, Caminati M, Menzella F, Milanese M, Rolla G, Lombardi C, et al. One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulm Pharmacol Ther. 2019;58: 101836.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"1597_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/02770903.2019.1658208","volume":"58","author":"B Pertzov","year":"2021","unstructured":"Pertzov B, Unterman A, Shtraichman O, Shitenberg D, Rosengarten D, Kramer MR. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma. 2021;58(1):79\u201384.","journal-title":"J Asthma"},{"issue":"7","key":"1597_CR29","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/cea.13613","volume":"50","author":"C Pelaia","year":"2020","unstructured":"Pelaia C, Crimi C, Pelaia G, Nolasco S, Campisi R, Heffler E, et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020;50(7):780\u20138.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"1597_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jaip.2014.02.011","volume":"2","author":"AT Luskin","year":"2014","unstructured":"Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544-52.e1-2.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9842","key":"1597_CR31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139.","journal-title":"Lancet"},{"issue":"9","key":"1597_CR32","volume":"9","author":"HA Farne","year":"2017","unstructured":"Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9(9): Cd010834.","journal-title":"Cochrane Database Syst Rev"},{"key":"1597_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1753466620929231","volume":"14","author":"GE Carpagnano","year":"2020","unstructured":"Carpagnano GE, Pelaia C, D\u2019Amato M, Crimi N, Scichilone N, Scioscia G, et al. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020;14:1\u201313.","journal-title":"Ther Adv Respir Dis"},{"issue":"7","key":"1597_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549\u201356.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"1597_CR35","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521\u201337.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1597_CR36","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/all.12914","volume":"71","author":"A Magnan","year":"2016","unstructured":"Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71(9):1335\u201344.","journal-title":"Allergy"},{"key":"1597_CR37","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS). Informe de posicionamiento terap\u00e9utico PT-mepolizumab\/V1\/27102016. 2016"},{"issue":"3","key":"1597_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.opresp.2020.03.005","volume":"2","author":"\u00c1-GF Javier","year":"2020","unstructured":"\u00c1lvarez Guti\u00e9rrez FJ, Blanco Aparicio M, Plaza V, Cisneros C, Garc\u00eda Rivero JL, Padilla A, et al. Documento de consenso de asma grave en adultos. Actualizaci\u00f3n 2020. Open Respir Arch. 2020;2(3):158\u201374.","journal-title":"Open Respir Arch."}],"updated-by":[{"DOI":"10.1007\/s40265-021-01622-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01597-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01597-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01597-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T02:17:38Z","timestamp":1635301058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01597-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01597-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"20 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01622-x","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01622-x","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by GlaxoSmithKline (study number 213172).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CDR has received funding for travel or speaker fees from ALK, Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, Esteve, Ferrer, GSK, Menarini, Novartis, Stallergenes and Pfizer. TCD has received speaker fees from ALK, Diater, GSK, LETI and Novartis. MBA has received speaker or consulting fees from ALK, AstraZeneca, Chiesi, GSK, Novartis, Teva and Zamb\u00f3n. EMM has received speaker or consulting fees from ALK, AstraZeneca, BIAL, Boehringer Ingelheim, Chiesi, GSK, Novartis, Teva, and Sanofi. DBC and MGSH are employees of GSK. CDR, TCD, MBA and EMM declare no specific conflicts of interest to report regarding this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and order SAS\/3470\/2009. Approval was granted by the Ethics Committee of Hospital La Princesa, Madrid, on 25 September 2019.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent obtained included the publication of participants\u2019 aggregate and anonymized health data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"CDR, DBC, MGSH, TCD, MBA, EMM reviewed the literature and critically edited the manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}